Back story.
In a move that could help preserve its lucrative monopoly on an important anemia drug, Amgen has reached an agreement that will make it the sole supplier of the drug to one of the nation’s two main operators of kidney dialysis centers.
The deal, announced yesterday by the dialysis provider, Fresenius Medical Care, comes as Roche is preparing to enter the market next year with a drug that would offer the first competition to Amgen’s drug, which is known as Epogen.
Now, it appears, Roche will not be able to sell its drug to Fresenius, which represents about 35 percent of the American dialysis market.
NYTimes
No comments:
Post a Comment